Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flonoltinib Maleate in Intermediate- or High-risk Myelofibrosis
NCT07443306Phase 2Recruiting
- Sponsor
- Zenitar
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of flonoltinib in myelofibrosis (MF), sponsored by Zenitar. Started Mar 2026; status: recruiting.
02
Drugs
flonoltinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT07443306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07443306.